Abstract Amyloid beta (Ab) was shown to bind the 75 kD neurotrophin receptor (p75 NTR ) to induce neuronal death. We synthesized a p75 NTR antagonistic peptide (CATDIKGAEC) that contains the KGA motif that is present in the toxic part of Ab and closely resembles the binding site of NGF for p75 NTR . In vivo injections of Ab into the cerebral cortex of B57BL/6 mice together with the peptide produced significantly less inflammation than simultaneous injections of Ab and a control (CKETIADGAC, scrambled) peptide injected into the contralateral cortex. These data suggest that blocking the binding of Ab to p75 NTR may reduce neuronal loss in Alzheimer's disease.
Introduction
Neuronal death in the presence of beta amyloid (Ab) characterizes Alzheimer's disease (AD). We have demonstrated (Yaar et al. 1997 (Yaar et al. , 2002 and others have confirmed (Kuner et al. 1998; Perini et al. 2002; Tsukamoto et al. 2003 ) that Ab induces apoptosis/ necrosis of neurons by binding the 75 kD transmembrane neurotrophin receptor (p75 NTR ), activating nuclear NFjB (Kuner et al. 1998) as well as capsases 8, 9, and 3 (Perini et al. 2002) . Our previous in vitro work has demonstrated that a p75 NTR antagonistic cyclic peptide (CATDIKGAEC) interferes with Ab signaling and rescues neurons from Ab-induced toxicity (Yaar et al. 2007) . p75 NTR interacts with receptors of the trk family, increasing receptor affinity for neurotrophins and leading to several beneficial effects on neurons including survival [reviewed in (Ibanez 2002) . However, certain ligands like Ab bind and activate p75 NTR alone, without coordinate binding to receptors of the trk family, and induce cell death (Yaar et al. 1997 (Yaar et al. , 2002 . Ibanez et al. (1992) showed that amino acids 29-35 (TDIKGKE) of NGF, that form one of its b hairpin loop structures, mediate p75 NTR binding , and if K (lysine) in position 34 is replaced by A (alanine), the resulting NGF mutant still binds p75 NTR but with 50% lower affinity (Ibanez et al. 1992) . Interestingly, amino acid residues 28-30 of Ab are KGA, and computerized structure analysis of Ab suggests that these residues have a high probability of being in a b-loop configuration (White et al. 1994) , constituting a receptor binding site. Indeed, a cyclic peptide containing the KGA motif that specifically binds p75 NTR but not p140 trkA , prevents Ab-induced apoptotic signaling and prevents Ab-induced neuronal death in vitro (Yaar et al. 2007) .
We now report that in vivo injections of Ab together with this p75 NTR antagonistic cyclic peptide into the cerebral cortex of mice produced significantly less inflammation than simultaneous injections of Ab and a control peptide. Blocking Ab binding to p75 NTR may provide a novel approach to arresting the progression of AD.
Materials and Methods

Materials and Animals
The cyclic peptides were purchased from BioSource International. Ab (1-42) (Quality Controlled Biochemicals, Hopkinton, MA) was dissolved in sterile distilled water (0.2 mM) and incubated at 37°C for 1 day before use to allow peptide aggregation. About 14-16-week-old male C57BL/6 wild type (WT) or p75 NTR -null (p75 NTR-/-) mice (Charles River Laboratories, Wilmington, MA) were used. Animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by both the Veteran's Affairs and Boston University Animal Care committees.
Experimental Design
Two experiments were performed. In the first experiment mice received stereotactic injections of Ab (1-42, 0.2 mM) and diluent, or Ab (0.2 mM) plus antagonistic cyclic peptide (0.25 lM, 1 lM, or 10 lM) into the cerebral cortexes as described (Kowall et al. 1992) . Animals were sacrificed 7 days later and brains were processed for analysis. The entire brain was sectioned (each section 35 lm thick) and at least 18 sections including a negative (lesion-free) section at each end were collected and stained with cresyl violet (CV) to identify inflammatory cells (Kowall et al. 1992 ). In the second experiment, mice (n = 15) were injected with Ab and p75 NTR antagonistic cyclic peptide (CATDIKGAEC) to one hemisphere as above, or Ab and a scrambled peptide (CKETIADGAC) as control to the contralateral hemisphere. Brain sections were processed as above, the extent of inflammatory infiltrate was identified manually in each section and the total area occupied by inflammatory cells was determined [Macintosh scanner IPlab spectrum software (Signal Analytics, Vienna, VA)].
Results
Visual inspection of CV-stained sections showed that the inflammatory infiltrate surrounding brain areas injected with Ab alone was consistently larger than that produced in contralateral sites injected with Ab and the cyclic peptide (Fig. 1 ). Brain lesions in hemispheres injected with the antagonistic cyclic peptide in addition to Ab were significantly smaller than those produced by injections of Ab and the scrambled peptide (P \ 0.025, paired t-test).
To further confirm the role of p75 NTR in Abinduced inflammation, wild type (WT, n = 18) or p75 NTR -null (p75 NTR-/-, n = 22) C57BL/6 mice were injected with Ab (0.2 mM) to one cortical hemisphere and diluent to the contralateral hemisphere, and total lesion area was determined as above. In WT mice brain lesions in Ab injected hemispheres were 75 ± 24% (mean ± SEM) larger than in diluent injected hemispheres (P \ 0.02, paired t-test). However, in p75 NTR-/-mice, brain lesions in Ab injected hemispheres were only 27 ± 21% (mean ± SEM) larger than in diluent injected hemispheres (P = 0.56, paired t-test). Thus, in mice lacking p75
NTR there was no significant difference in inflammation between Ab and diluent alone.
Discussion
Neuroinflammation in Alzheimer's disease contributes to the brain's response to Ab deposits and to the ensuing neuronal apoptosis and necrosis (reviewed in (Stege and Bosman 1999; Tan et al. 1998; Yaar et al. 1997) ). Activated microglia and astrocytes are recruited to the area and assemble within and around Ab plaques (El Khoury et al. 1996) . Together with T lymphocytes, these cells are activated to produce inflammatory mediators including cytokines IL-1b, IL-6, TNF-a, and monocyte chemoattractant protein 1 (Stege and Bosman 1999) . Additionally, these inflammatory cells produce reactive oxygen species (ROS) (Tan et al. 1998 ) and nitric oxide (Goodwin et al. 1995) , ultimately increasing neuronal injury and inflammation. Interestingly, inflammatory cell cytokines like IL-1 enhance Ab synthesis (Goldgaber et al. 1989 ) and are then activated by newly synthesized Ab to produce more inflammatory mediators, generating a positive feedback cycle that further aggravates neuronal injury (Klegeris et al. 1994) . Although innate immune responses to injurious stimuli is generally beneficial, a prolonged response such as that present in AD is detrimental, adversely affecting vulnerable neurons and leading to further neuronal degeneration (Craft et al. 2005) .
Injections of Ab into murine cortex was reported to produce areas positive for glial fibrillary acidic protein immunoreactivity, increased astrocyte density, and increased level of markers for oxidative damage (Klein et al. 1999) . In aged primates, Ab intracerebral injections produced lesions containing argyrophilic, thioflavine S fluorescent, Alz 50, and ubiquitin immunoreactive neurons (McKee et al. 1998) , demonstrating Ab neurotoxicity, and possibly identifying the initial damage caused by Ab deposition in the brain. Here we report that a p75 NTR antagonistic cyclic peptide, known to block Abinduced neuronal death in vitro (Yaar et al. 2007 ), decreases inflammation in cerebral cortices of mice injected with Ab together with the antagonistic cyclic peptide as compared to those injected with Ab and a control scrambled peptide.
Senile plaques in AD are characterized by extracellular accumulation of Ab containing primarily Ab42 (Knauer et al. 1992) . Although in humans these plaque evolve over many years, when Ab42 is injected into murine cortex it rapidly leads to ADlike changes, primarily recruitment of activated glial cells and increased level of ROS (determined by immunostaining for 8-hydroydeoxyguanosine) (Klein et al. 1999; Kowall et al. 1991) , leading to neuronal degeneration (Kowall et al. 1991) . Using this murine model, we show a beneficial anti-inflammatory effect of a p75 NTR antagonistic cyclic peptide, not observed with an irrelevant scrambled cyclic peptide or in mice lacking p75
NTR . The studies, however, do not provide information on the cyclic peptide ability to prevent neuronal death in vivo or on its long-term effects in preventing the reported pathological, biochemical, and behavioral decrements associated with Alzheimer's disease. However, in combination with the prior in vitro observation that the cyclic peptide NTR antagonistic cyclic peptide (b). Representative sections of the cerebral cortex stained with CV show that the inflammatory infiltrate, apparent along the injection track, is more extensive and more intense in (a) than in (b) (original magnification 9100). (c) C57BL/6 mice were injected with Ab and p75 NTR antagonistic cyclic peptide or Ab and scrambled peptide. Graphic representation of lesion size averaged over all mice. There is a statistically significant difference in lesion size between the hemispheres injected with Ab and scrambled (control) peptide versus Ab and p75 NTR antagonistic (active) peptide (P \ 0.025). Mean ± SEM are displayed prevents Ab-mediated neuronal apoptosis/necrosis (Yaar et al. 2007 ) the data suggest that the recruitment of microglia and other inflammatory cells that would have otherwise been activated in response to neuronal injury (Stege and Bosman 1999; Tan et al. 1998; Yaar et al. 1997) . Indeed, degenerating neurons are known to release pro-inflammatory mediators such as heat shock proteins and interleukins (IL-1 and -8) to recruit and activate inflammatory cells (Gupta et al. 2006) . Alternately, or in addition, microglia and astrocytes are known to express p75 NTR (Heese et al. 1998; Perini et al. 2002) and to be activated by Ab to produce a variety of inflammatory mediators (El Khoury et al. 1996; Goodwin et al. 1995; Klegeris et al. 1994) . Some of these mediators like TNF-a and IL-1b synergize with Ab to enhance neuronal degeneration (Perini et al. 2002) . Thus, by interfering with Ab binding to p75 NTR in glial cells, p75 NTR antagonistic cyclic peptide may prevent their activation and thus decrease the inflammatory response. Regardless of mechanism, our studies suggest that inhibiting the binding of Ab to p75 NTR may have the beneficial effect of slowing the progression of AD.
